Jazz Pharmaceuti (JAZZ)
$138.51
0.55 (0.40%)
JAZZ Stock Quote Delayed 30 Minutes
GW Pharmaceuticals Earnings: GWPH Stock Soars as Q1 Revenue Triples
GW Pharmaceutical reported its quarterly earnings results late on Tuesday, bringing in revenue that was thrice the amount it was a year ago.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$136.05
Market Cap
8.38B
PE Ratio
16.32
EPS
8.4869
Volume (Avg. Vol.)
995,298
Day's Range
$135.25 - $138.20
52-Week Range
$99.06 - $148.06
Dividend & Yield
N/A (N/A)
JAZZ Stock Predictions, Articles, and Jazz Pharmaceuti News
GW Pharmaceuticals (GWPH) Stock Is Sliding on Q4 Revenue Miss
GW Pharmaceuticals (GWPH) stock is down more than 5% as the company's fourth-quarter revenue came in below what analysts were projecting.
Marijuana Stocks: GW Phamaceuticals Stock Surges on Late-Stage Study Success
There was good news for marijuana stocks today after GW Phamaceuticals (GWPH) announced recent results from a late-stage study.
5 Safe Stocks to Buy With Low Price-to-Book Ratios
P/B ratio is a convenient tool to identify low-priced stocks that have high-growth prospects. Here are five stocks with low P/B ratios.
New Age Beverages Stock Bubbles Higher on Upcoming CBD Drinks Launch
New Age Beverages stock got a bit of a boost on Friday as the company prepares to launch its upcoming CBD drinks in select states.
GW Pharmaceuticals Stock Surges on Epilepsy Drug News
GW Pharmaceuticals stock was on the rise Thursday following news of its epilepsy drug Epidiolex getting a Class V rating.
GWPH Stock Surges on Reclassification of Epidiolex
GWPH stock was up over 2.7% as the DEA is set to reclassify Epidiolex (cannabidiol) to be allowed for medicinal use in the coming months.
Do the Risks in Marijuana Stocks Outweigh the Rewards?
When looking at marijuana stocks, it's important to remember that how you play a big sector rally matters most. Here's what you need to know about stocks based in the cannabis space.
Why the Cannabis Market (And These Cannabis Stocks) Could Be Huge
The cannabis market has $100 billion-plus potential, but cannabis stocks won't start to realize that potential until a few years down the road.
GW Pharmaceuticals (GWPH) Stock Remains Flat as Loss Widens
GW Pharmaceuticals (GWPH) stock remained unchanged after hours on Tuesday despite the company posted a loss that was wider than it was in the year-ago quarter.
5 Low Price-to-Book Stocks Worth Buying in July
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects. Compare Brokers....
CBD Medicine Developments Provide a Really Solid Base for GWPH Stock
For those unfamiliar with Dravet syndrome, it’s a rare genetic condition that hits newborns and results in seizures caused by fever and involuntary muscle spasms. Young children who develop this condition tend to experience difficulty speaking, reduced motor skills, and hyperactivity.
Here’s the Reason that GWPH Stock Tumbled Despite Regulatory Victory
Although GW Pharmaceuticals scored a major regulatory win, GWPH stock fell due to the specter of political headwinds.
